



## Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024

January 2, 2024

– Presentation to be webcast on [www.exelixis.com](http://www.exelixis.com) –

ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 2, 2024-- Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview at the 42<sup>nd</sup> Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT / 7:30 p.m. ET.

To access the webcast link, log onto [www.exelixis.com](http://www.exelixis.com) and proceed to the Event Calendar page under the Investors & News heading. A replay will also be available at the same location for at least 30 days.

### About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by bi-coastal centers of discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX<sup>®</sup> (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit [www.exelixis.com](http://www.exelixis.com), follow [@ExelixisInc](https://twitter.com/ExelixisInc) on X (Twitter), like [Exelixis, Inc.](https://www.facebook.com/Exelixis) on Facebook and follow [Exelixis](https://www.linkedin.com/company/exelixis) on LinkedIn.

*Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.*

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240102006946/en/): <https://www.businesswire.com/news/home/20240102006946/en/>

### Investors Contact:

Varant Shirvanian  
Associate Director, Investor Relations  
Exelixis, Inc.  
650-837-7917  
[vshirvanian@exelixis.com](mailto:vshirvanian@exelixis.com)

### Media Contact:

Hal Mackins  
For Exelixis, Inc.  
415-994-0040  
[hal@torchcommunications.com](mailto:hal@torchcommunications.com)

Source: Exelixis, Inc.